title: Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation.
abstract: Liposomes have been used widely to improve the therapeutic activity of pharmaceutical agents. The traditional approach for such applications has been to formulate the pharmaceutical agent in liposomes prior to administration in vivo. In this report we demonstrate that liposomes exhibiting a transmembrane pH gradient injected intravenously (iv) can actively encapsulate doxorubicin in the circulation after iv administration of free drug. Small (110 nm) liposomes composed of phosphatidylcholine (PC)/cholesterol (Chol, 55:45 mol:mol) exhibiting a pH gradient (inside acidic) were administered iv 1 h prior to free doxorubicin, and plasma drug levels as well as toxicity and efficacy were evaluated. Predosing with egg PC/Chol pH gradient liposomes increased the plasma concentration of doxorubicin as much as 200-fold compared to free drug alone as well as to predosing with dipalmitoyl PC/Chol pH gradient liposomes or EPC/Chol liposomes without a pH gradient. The ability of the liposomes to alter the pharmacokinetics of doxorubicin was dependent on the presence of a transmembrane pH gradient and correlated with the extent of doxorubicin uptake into the liposomes at 37 degreesC in pH 7.5 buffer, indicating that doxorubicin was being actively accumulated in the circulating liposomes. This in vivo drug loading was achieved over a range of doxorubicin doses (5 mg/kg-40 mg/kg) and was dependent on the dose of EPC/Chol liposomes administered prior to free doxorubicin injection. The altered pharmacokinetic properties of doxorubicin associated with in vivo doxorubicin encapsulation were accompanied by a decrease in drug toxicity and maintained antitumor potency. These results suggest that pretreatment with empty liposomes exhibiting a pH gradient may provide a versatile and straightforward method for enhancing the pharmacological properties of many drugs that can accumulate into such vesicle systems at physiological temperatures.
authors.affiliation: Advanced Therapeutics Department BC Cancer Agency 600 West 10th Avenue, Vancouver, B.C. V5Z 4E6, Canada.lmayer@bccancer.bc.ca
authors.forename: L D
authors.initials: LD
authors.lastname: Mayer
authors.forename: J
authors.initials: J
authors.lastname: Reamer
authors.forename: M B
authors.initials: MB
authors.lastname: Bally
mesh_terms: D000818:Animals; D004317:Doxorubicin / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity*; D004337:Drug Carriers; D004339:Drug Compounding; D005260:Female; D006863:Hydrogen-Ion Concentration; D007275:Injections, Intravenous; D007939:Leukemia L1210 / Q000188:drug therapy; D008081:Liposomes; D051379:Mice; D008811:Mice, Inbred DBA
chemical_list: D004337:Drug Carriers; D008081:Liposomes; D004317:Doxorubicin